ALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Jaume Pons Sells 10,796 Shares

ALX Oncology Holdings Inc. (NASDAQ:ALXO) insider Jaume Pons sold 10,796 shares of the business’s stock in a transaction on Monday, December 30th. The shares were sold at an average price of $1.58, for a total transaction of $17,057.68. Following the completion of the transaction, the insider now owns 580,714 shares of the company’s stock, valued at approximately $917,528.12. This represents a 1.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

ALX Oncology Price Performance

ALXO traded down $0.11 on Thursday, reaching $1.56. 759,703 shares of the company’s stock were exchanged, compared to its average volume of 830,562. ALX Oncology Holdings Inc. has a twelve month low of $1.19 and a twelve month high of $17.83. The stock has a market cap of $82.28 million, a PE ratio of -0.52 and a beta of 1.04. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.82 and a quick ratio of 4.82. The stock’s fifty day moving average price is $1.52 and its 200-day moving average price is $2.90.

Analysts Set New Price Targets

A number of research firms have weighed in on ALXO. Jefferies Financial Group cut shares of ALX Oncology from a “buy” rating to a “hold” rating and cut their price objective for the company from $12.00 to $2.00 in a report on Thursday, December 19th. Cantor Fitzgerald reissued an “overweight” rating on shares of ALX Oncology in a report on Wednesday, December 18th. Finally, HC Wainwright reiterated a “buy” rating and set a $25.00 price objective on shares of ALX Oncology in a research note on Wednesday, December 18th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $8.50.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in ALX Oncology by 394.8% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock worth $39,000 after purchasing an additional 5,200 shares during the period. Hsbc Holdings PLC acquired a new stake in ALX Oncology during the second quarter worth $63,000. AQR Capital Management LLC raised its position in ALX Oncology by 50.7% in the second quarter. AQR Capital Management LLC now owns 18,079 shares of the company’s stock valued at $109,000 after purchasing an additional 6,080 shares during the period. SG Americas Securities LLC lifted its stake in shares of ALX Oncology by 33.6% in the 3rd quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock valued at $50,000 after purchasing an additional 6,888 shares during the last quarter. Finally, Algert Global LLC purchased a new position in shares of ALX Oncology during the 2nd quarter worth $249,000. 97.97% of the stock is currently owned by institutional investors and hedge funds.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.